Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing a new generation of precision oncology medicines. Leveraging the genetic principle of synthetic lethality, Tango aims to create therapies that target specific cancer vulnerabilities, offering novel treatment options for patients. Their primary focus is on identifying and drugging novel targets to deliver transformative therapies for cancers with high unmet medical need. Key programs include TNG908 (PRMT5 inhibitor for MTAP-deleted tumors) and TNG462 (next-generation PRMT5 inhibitor), alongside a pipeline of discovery-stage assets.
The Boston headquarters serves as the central nexus for Tango Therapeutics' research and development, clinical operations, corporate strategy, and administrative functions.
Situated in a modern life sciences building, the facility is equipped with state-of-the-art laboratories for drug discovery and translational research, alongside collaborative office spaces designed to foster scientific innovation.
Tango Therapeutics fosters a science-driven, innovative, and collaborative work environment. The culture emphasizes urgency and a commitment to addressing unmet needs in oncology, with teams dedicated to rigorous scientific inquiry and translational medicine.
Its location in the Boston/Cambridge biotech ecosystem provides Tango with access to world-class scientific talent, leading academic research institutions, and a vibrant network of collaborators and service providers, crucial for advancing its drug development programs.
While headquartered in the United States, Tango Therapeutics's operations, particularly clinical trials for its drug candidates, have a global reach. The company collaborates with clinical trial sites and investigators internationally to evaluate the safety and efficacy of its novel oncology treatments in diverse patient populations.
201 Brookline Avenue, Suite 601
Boston
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Tango Therapeutics' leadership includes:
Tango Therapeutics has been backed by several prominent investors over the years, including:
In the last 12 months (approx. June 2023 - June 2024), Tango Therapeutics strengthened its executive leadership with the appointment of a new General Counsel. There were no publicly announced departures of named executive officers during this period, although a company-wide restructuring impacting overall headcount occurred in May 2024.
Discover the tools Tango Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Tango Therapeutics likely uses a standard corporate email format. Based on common patterns in the biopharmaceutical industry and available information, the most probable format is the first initial followed by the last name.
[first_initial][last]@tangotx.com
Format
jdoe@tangotx.com
Example
75%
Success rate
GlobeNewswire • June 3, 2024
Tango Therapeutics presented positive updated data from its Phase 1/2 trial of TNG908, an MTA-cooperative PRMT5 inhibitor, demonstrating encouraging anti-tumor activity and a manageable safety profile in patients with MTAP-deleted solid tumors....more
GlobeNewswire • May 7, 2024
Tango Therapeutics announced a corporate restructuring, including an approximately 20% reduction in its workforce, to focus resources on its lead clinical programs (TNG908, TNG462) and its discovery-stage PRMT5 inhibitor program (TNG260), aiming to extend its cash runway into 2027....more
GlobeNewswire • May 7, 2024
Tango Therapeutics reported its Q1 2024 financial results, highlighting progress in its clinical pipeline and outlining strategic priorities following its corporate restructuring. The company reiterated its focus on advancing its key oncology programs....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Tango Therapeutics, are just a search away.